Navigation Links
Simbionix Announces Initiation of the REHEARSAAAL Study
Date:10/24/2013

CLEVELAND, October 24, 2013 /PRNewswire/ --

Simbionix, a leading provider of innovative training solutions, announced the initiation of the REHEARSAAAL study which evaluates the clinical benefits of preoperative patient specific simulation using the PROcedure Rehearsal Studio™ for the treatment of Abdominal Aortic Aneurysms (AAAs) by Endovascular Aortic Repair (EVAR). This study will be conducted by multidisciplinary group of physicians from vascular surgery, interventional radiology and cardiology departments in hospitals across the United States and Europe.

     (Logo: http://photos.prnewswire.com/prnh/20120502/529202-a)

PROcedure Rehearsal Studio allows physicians to create a 3D anatomical model based on a patient's individualized CT scan to simulate, analyze and evaluate preoperative surgical options. The availability of patient specific technology allows the interventional team to engage in simulated practice procedures utilizing a patient's own anatomy prior to performing an actual procedure, potentially leading to more precise treatment decisions, a reduction of errors, improved outcomes, and enhanced operator confidence.  Prior case simulation may allow patients to have a shortened procedure with less time under sedation, a reduction in radiation exposure, and a decrease in procedural complications.

This two-arm study will randomize 150 patients in 1:1 ratio, stratified by operator's experience and procedure complexity. It compares real EVAR procedure parameters with an emphasis on radiation exposure time and safety parameters. Physicians treating patients enrolled for the preoperative patient specific simulation group will go through the simulated experience - a virtual practice session - prior to performing the real case.  Outcomes in these patients will be compared to procedures performed without prior simulated practice as is routinely done.

Dr. John Rundback, Medical Director, Interventional Institute at Holy Name Medical Center and the study's Principal Investigator, "Simulation has proven experience in the aviation and other industries in improving performance and reducing errors. The Simbionix PROcedure Rehearsal Studio provides a platform to practice and optimize procedures using personalized patient data in advance of performing live cases, assuring an unparalleled opportunity to streamline all aspects of the actual procedure, improve patient safety, and reduce the use of additional costly devices that are often needed when procedures are unable to be rehearsed."

See the PROcedure Rehearsal Studio at TCT in booth # 2408 and at VEITH in booth # 110.

About Simbionix:

Simbionix is committed to delivering quality products, advancing clinical performance and optimizing procedural outcomes. http://www.simbionix.com

Rebecca Levy, Marketing Communications Manager, rebecca@simbionix.com; +1-216-229-2070#128


'/>"/>
SOURCE Simbionix Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Após o sucesso do lançamento nos Estados Unidos, o novo U/S Mentor da Simbionix será introduzido pela primeira vez na Europa
2. Inflamax Research, Inc. Announces Fully-Integrated Clinical e-Source Data Management Services
3. The Comfort Outlet Announces No Shipping Costs on All Outlast Mattress Pads
4. Brainwave Signal Interpretation Software Company EyeMynd Announces Move to Silicon Valley
5. The Conference Forum Announces the Launch of the 2nd Annual Medicaid Rebate Summit
6. Genufood Energy Enzymes Corp. Announces $20 Million Equity Purchase Agreement
7. Elan Wellness Center Announces Theralase Therapeutic Laser Treatment is Now Available
8. Jeeven BioSciences, Inc. Announces the Release of Its Neuro-XTM Serum-Free and Xeno-Free Tissue Culture Media
9. Spartan Bioscience Announces Medical Device Registration of Rapid CYP2C19 Testing System in Saudi Arabia
10. TM&S, LLC Announces Representation of ecoMIM
11. QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... of medical marijuana products targeting the needs of consumers who are incorporating medical ... takes place in Phoenix, Arizona. , As operators of two successful Valley dispensaries, ...
Breaking Biology Technology:
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):